ESPOIR and the French database management: what have we learned from the first years of follow-up?

被引:0
|
作者
Combe, B. [1 ]
机构
[1] Univ Montpellier, Hop Lapeyronie, Dept Rhumatol, F-34059 Montpellier, France
关键词
ESPOIR cohort; rheumatoid arthritis; early arthritis; undifferentiated arthritis; outcome; EARLY RHEUMATOID-ARTHRITIS; RECENT-ONSET POLYARTHRITIS; RADIOGRAPHIC PROGRESSION; CLASSIFICATION CRITERIA; EROSIVE DISEASE; COHORT; EQ-5D; RA; RECOMMENDATIONS; METHOTREXATE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ESPOIR (Etude et Suivi des POlyarthrites Indifferenciees Recentes) is a multicentre national cohort sponsored by the French Society for Rheumatology. The patients had early arthritis (< 6-month disease duration), had a certain/probable clinical diagnosis of RA or undifferentiated arthritis potentially becoming RA and were DMARDs or glucocorticoids naive. ESPOIR is a cohort of early arthritis, highly enriched for rheumatoid arthritis (RA) patients, since in patients followed for 5 years more than 90% met ACR/EULAR criteria for RA. A total of 813 patients were enrolled between December 2002 and March 2005 in 14 academic regional centres with the participation of a network of private rheumatologists. Today, 104 clinical research projects have been selected by the scientific committee of the cohort. The projects focus on data from the first 5 years of follow-up. Many studies are in progress, and 54 original articles have been published. The research projects cover a wide range of topics, including environmental factors, diagnosis, evolution, and prognosis, evaluation of disease, imaging, genetics, biomarkers, medical economics and therapeutic strategies.
引用
收藏
页码:S153 / S157
页数:5
相关论文
共 50 条
  • [41] What have we learned from research into first-episode psychosis?
    Bernardo, Miguel
    Bioque, Miquel
    REVISTA DE PSIQUIATRIA Y SALUD MENTAL, 2014, 7 (02): : 61 - 63
  • [42] What we have learned from helioseismology
    Thompson, MJ
    ASTROPHYSICS AND SPACE SCIENCE, 1998, 261 (1-4) : 23 - 34
  • [43] What have we learned from OpenReview?
    Wang, Gang
    Peng, Qi
    Zhang, Yanfeng
    Zhang, Mingyang
    WORLD WIDE WEB-INTERNET AND WEB INFORMATION SYSTEMS, 2023, 26 (02): : 683 - 708
  • [44] WHAT WE HAVE LEARNED FROM CHERNOBYL
    LUSHBAUGH, CC
    DISCHER, DP
    WESTERN JOURNAL OF MEDICINE, 1988, 148 (01): : 76 - 77
  • [45] What have we learned from SHIVA?
    Le Tourneau, Christophe
    Kurzrock, Razelle
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (12) : 719 - 720
  • [46] What have we learned from BeSt?
    Allaart, Cornelia F.
    Markusse, Iris M.
    Lems, Willem F.
    CLINICAL IMMUNOLOGY, 2018, 186 : 74 - 78
  • [47] What have we learned from the pandemic?
    Holcomb, Liz
    NURSE RESEARCHER, 2022, 30 (02) : 5 - 5
  • [48] What have we learned from nonimmobilizers?
    Eger, EI
    MOLECULAR AND BASIC MECHANISMS OF ANESTHESIA, 2002, : 58 - 60
  • [49] What have we learned from SHIVA?
    Christophe Le Tourneau
    Razelle Kurzrock
    Nature Reviews Clinical Oncology, 2016, 13 : 719 - 720
  • [50] What Have We Learned from OpenReview?
    Wang, Gang
    Peng, Qi
    Zhang, Yanfeng
    Zhang, Mingyang
    WEB AND BIG DATA, APWEB-WAIM 2021, PT I, 2021, 12858 : 63 - 79